Abstract:PurposePaclitaxel has been reported to upregulate both AKT and MAPK signaling pathways and thereby compromises its antitumor efficacy. However, tunicamycin has the ability to downregulate AKT and MAPK pathways. The aim of the study is to investigate the antitumor activity of the combination treatment of paclitaxel with tunicamycin and the mechanisms involving the changes of antitumor efficacy.MethodsSulforhodamine B (SRB) assay was used to examine the cell viability upon treatment of breast cancer cells with paclitaxel, tunicamycin and the combination of both. Cell cycle distributions and apoptosis were detected by flow cytometry. Western blotting and immunofluorescence staining were used to analyze the effect of drugs on tubulin polymerization. The antitumor growth of combined treatment was measured in nude mice bearing MDA-MB-231 xenograft. Western blotting was performed to explore the alteration of AKT and MAPK pathways in vitro and in vivo.ResultsSRB assay and nude mice experiment showed that tunicamycin synergistically enhanced paclitaxel-induced inhibition of cell proliferation and tumor growth. Tunicamycin had no clear effect on paclitaxel-induced cell cycle arrest, demonstrating that cell cycle distribution was not involved in the enhanced antitumor activity. Both annexin V-FITC/propidium iodide assay and TUNEL assay indicated that the combination of tunicamycin with paclitaxel resulted in significant increased cell apoptosis as compared with individual treatment in vitro and in vivo. Tunicamycin decreased paclitaxel-induced microtubulin polymerization, suggesting that enhanced antitumor effect of paclitaxel was not dependent of microtubulin polymerization. Western blotting analysis confirmed that tunicamycin decreased paclitaxel-induced upregulation of survival signal pathways such as AKT and MAPK.ConclusionThese results revealed that tunicamycin synergistically enhanced the antitumor effects of paclitaxel through potentiating apoptosis via inhibiting paclitaxel-induced elevation of AKT and MAPK pathways. This study raised the possibility that the combination of paclitaxel with tunicamycin may be a promising approach for improving the clinical activity of paclitaxel.

Antagonistic Interplay Between Antimitotic and G1-S Arresting Agents Observed in Experimental Combination Therapy.

The Inhibiting Effect of Combination of Allicin with Paclitaxel on Proliferation of Gastric Cancer Cells and Promotion of Apoptosis

Combination of Gemcitabine Antagonizes Antitumor Activity of Paclitaxel Through Prevention of Mitotic Arrest and Apoptosis

Cell Cycle-Dependent Antagonistic Interactions Between Paclitaxel and Gamma-Radiation in Combination Therapy

Reduced Expression of P53 and P21(Waf1/Cip1) Sensitizes Human Breast Cancer Cells to Paclitaxel and Its Combination with 5-Fluorouracil

G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy

Cell Cycle Dependent Antagonistic Interactions Between Paclitaxel and Carboplatin in Combination Therapy.

Post-slippage Multinucleation Renders Cytotoxic Variation in Anti-Mitotic Drugs That Target the Microtubules or Mitotic Spindle.

Synergistic Effects of Apigenin and Paclitaxel on Apoptosis of Cancer Cells.

Possible mechanisms of paclitaxel-induced apoptosis.

Paclitaxel-Induced Apoptosis May Occur Without A Prior G(2)/M-Phase Arrest

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents

P-Glycoprotein-Independent Apoptosis Induction By A Novel Synthetic Compound, Mmpt [5-[(4-Methylphenyl)Methylene]-2-(Phenylamino)-4 (5h)-Thiazolone]

Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer

Effects of Combination of Gefitinib and Docetaxel on Various Tumor Cell Lines in Vitro

Sensitization of Decitabine Combined with Paclitaxel on Proliferation Inhibition and Apoptosis Induction of Paclitaxel-resistant MCF-7 Cells

Data from Synergistic Antitumor Activity of Gemcitabine and ABT-737 <i>In Vitro and In Vivo</i> through Disrupting the Interaction of USP9X and Mcl-1

Anti–mitotic Function of a Synthetic Compound MMPT Disrupting Microtubule Polymerization in Human Lung Cancer Cell Lines

Preclinical Development Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP 9 X and Mcl-1

Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro